head JofIMAB
Journal of IMAB - Annual Proceeding (Scientific Papers)
Publisher: Peytchinski Publishing Ltd.
ISSN: 1312-773X (Online)
Issue: 2023, vol. 29, issue3
Subject Area: Medicine
DOI: 10.5272/jimab.2023293.5099
Published online: 12 September 2023

Original article
J of IMAB. 2023 Jul-Sep;29(3):5099-5102
Ivaylo Pakov1ORCID logoCorresponding Autoremail, Adelaida Ruseva2ORCID logo, Irena Gencheva2ORCID logo, Tsetsa Doichinova1ORCID logo, Milena Karcheva1ORCID logo, Kalina Terzieva1ORCID logo, Lyudmila Pakova3, Biserka Vasileva4ORCID logo, Galya Gancheva1ORCID logo,
1) Department of Infectious Diseases, Epidemiology, Parasitology and Tropical Medicine, Faculty of Public Health, Medical University – Pleven, Bulgaria.
2) Department of Clinical Immunology, Allergology and Clinical Laboratory, Faculty of Health Care, Medical University – Pleven, Bulgaria.
3) Group Practice Outpatient Clinic for Primary Medical Care – “Dr Elina Stefanova and Dr Lyudmila Pakova” – OOD, Pleven, Bulgaria.
4) Department of Therapeutic Care, Faculty of Health Care, Medical University – Pleven, Bulgaria.

Combined antiretroviral therapy (cART) provides HIV-infected people life expectancy comparable with HIV-uninfected people and turns the disease into a manageable chronic condition necessitating the need for innovative inflammatory markers.
Our purpose was to determine the correlation between IL-6, D-dimer and high-sensitivity C-reactive protein (hsCRP) levels among HIV-infected and the presence of chronic inflammation during general and immunological aging and drug exposure.
Material and methods: Comparative prospective study was conducted at 37 HIV-positive persons from the Center for Monitoring and Treatment of HIV-positive Patients at the Clinic for Infectious Diseases, UMBAL “Dr. G. Stranski” – Pleven (target group) and 18 HIV-negative individuals from outpatient practice (control group), aged ≥18 years.
Results: The median age of seropositive persons was 40 years (24÷70 years), of the control group – 51 years (29÷72 years); 78% of the target group and 61% of the controls are men. The average duration of ART is 4 years (1÷9 years). The study of specified biomarkers in the target group found increased IL-6 in 8.11% of patients (mean 3.67±1.86 pg/mL; range 1.5÷8.62; 95% CI 3.11-5.02), increased D-dimer in 8.11% (mean 0.37±0.28 µg/mL; 0.21÷1.96; 95% CI 0.3691-0.37459) and increased hsCRP in 10.81% (mean 2.10±1.99 µg/mL; 0.19÷7.0; 95% CI 1.89-2.31). In the control group IL-6 was not increased (mean 2.75±1.67 pg/mL; 1.5÷6.91), D-dimer was increased in 16.67% (mean 0.37±0.17 µg/mL; 0.09÷0.8) and increased hsCRP – in 5.56% (mean 1.76±1.75 µg/mL; 0.19÷5.66). Il-6 was significantly higher in the target group.  
Conclusion: The implementation of sensitive biomarkers is crucial in the general diagnostic-therapeutic approach in aging with HIV.

Keywords: IL-6, D-dimer, hsCRP, chronic inflammation, HIV,

pdf - Download FULL TEXT /PDF 848 KB/
Please cite this article as: Pakov I, Ruseva A, Gencheva I, Doichinova T, Karcheva M, Terzieva K, Pakova L, Vasileva B, Gancheva G. IL-6, D-dimer and high-sensitivity C-reactive protein in HIV infection – preliminary study. J of IMAB. 2023 Jul-Sep;29(3):5099-5102. [Crossref - 10.5272/jimab.2023293.5099]

Corresponding AutorCorrespondence to: Ivaylo Nikolaev Pakov, Clinic of Infectious Diseases, University Hospital, Medical University – Pleven; 8A, Georgi Kochev Str., Pleven 5800, Bulgaria; E-mail: ivaylo.pakov@gmail.com

1. Global HIV&AIDS statistics - Fact sheet. UNAIDS. 2022. [Internet]
2. Wing E. The Aging Population with HIV Infection. Trans Am Clin Climatol Assoc. 2017; 128:131-44. [PMC]
3. Negredo E, Back D, Blanco JR, Blanco J, Erlandson KM, Garolera M, et al. Aging in HIV-Infected Subjects: A New Scenario and a New View. Biomed Res Int. 2017;2017:5897298. [ PubMed ]
4. Borges AH, O'Connor JL, Phillips AN, Neaton JD, Grund B, Neuhaus J, et al. Interleukin 6 is a Stronger Predictor of Clinical Events Than High-Sensitivity C-Reactive Protein or D-dimer During HIV Infection. J Infect Dis. 2016 Aug 1;214(3):408-16. [PubMed]
5. Serrano-Villar S, Cohen C, Baker JV, Janeiro MJ, Aragão F, Melbourne K, et al. Translating the observed differences in interleukin-6 levels between some antiretroviral regimens into potential long-term risk of serious non-AIDS events: A modeling study. Front Immunol. 2022 Nov 8;13:976564. [PubMed]
6.Velazquez-Salinas L, Verdugo-Rodriguez A, Rodriguez LL, Borca MV. The Role of Interleukin 6 During Viral Infections. Front Microbiol. 2019 May 10;10:1057. [PubMed
7. Grund B, Baker JV, Deeks SG, Wolfson J, Wentworth D, Cozzi-Lepri A, et al. Relevance of Interleukin-6 and D-dimer for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral Therapy. PLoS ONE. 2016 May 12;11(5): e0155100. [PubMed]
8. Siender MJ. START or SMART? Timing of Antiretroviral Therapy Initiation and Cardiovascular Risk for People with Human Immunodeficiency Virus Infection. Open Forum Infect Dis. 2016 Feb 9;3(1):ofw032. [PubMed]
9. Hamlyn E, Fidler S, Stöhr W, Cooper DA, Tambussi G, Schechter M, et al. Interleukin-6 and D-dimer levels at seroconversion as predictors of HIV-1 disease progression. AIDS. 2014 Mar 27;28(6):869-74. [PubMed]
10. Sun-Suslow N, Pasipanodya E, Morgan E, Kohli M, Serrano V, Letendre S, et al. Social support moderates D-dimer and self-realted successful aging with people with HIV and older adults. J Behav Med. 2020 Dec;43(6): 979-88. [PubMed]
11. Teasdale CA, Hernandez C, Zerbe A, Chege D, Hawken M, El-Sadr WM. Changes in D-dimer after initiation of antiretroviral therapy in adults living with HIV in Kenya. BMC Infect Dis. 2020 Jul 14;20(1):508. [PubMed]   

Received: 27 March 2023
Published online: 12 September 2023

back to Online Journal